Key Points
- Director Ramiro Guerrero purchased 37,595 MAIA shares at an average price of $1.32, investing $49,625.40 and increasing his direct ownership by 5.11% to 773,296 shares.
- Guerrero has made several additional purchases since August 20, bringing his recent buying activity to more than 185,000 shares and signaling continued insider accumulation.
- MAIA shares recently opened at $1.39, while the company reported a quarterly loss of $0.13 per share—$0.02 worse than analysts expected—and analysts forecast a full-year loss of $0.54 per share.
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Ramiro Guerrero bought 37,595 shares of MAIA Biotechnology stock in a transaction dated Thursday, September 10th. The stock was acquired at an average price of $1.32 per share, with a total value of $49,625.40. Following the purchase, the director directly owned 773,296 shares of the company's stock, valued at approximately $1,020,750.72. This represents a 5.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
Ramiro Guerrero also recently made the following trade(s):
- On Friday, August 28th, Ramiro Guerrero purchased 46,620 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.35 per share, for a total transaction of $62,937.00.
- On Thursday, August 27th, Ramiro Guerrero purchased 78,239 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.39 per share, for a total transaction of $108,752.21.
- On Wednesday, August 26th, Ramiro Guerrero purchased 8,931 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.39 per share, for a total transaction of $12,414.09.
- On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.33 per share, with a total value of $2,386.02.
- On Thursday, August 20th, Ramiro Guerrero acquired 11,899 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.37 per share, with a total value of $16,301.63.
MAIA Biotechnology Price Performance
Shares of MAIA stock opened at $1.39 on Tuesday. The company's fifty day simple moving average is $1.35 and its two-hundred day simple moving average is $1.39. MAIA Biotechnology, Inc. has a 1 year low of $0.87 and a 1 year high of $3.19. The stock has a market capitalization of $84.55 million, a price-to-earnings ratio of -2.24 and a beta of 0.25.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities research analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 EPS for the current year.
Institutional Trading of MAIA Biotechnology
Institutional investors have recently added to or reduced their stakes in the stock. PVG Asset Management Corp bought a new position in MAIA Biotechnology in the 1st quarter worth about $46,000. Susquehanna International Group LLP bought a new stake in shares of MAIA Biotechnology during the second quarter valued at about $51,000. Corsair Capital Management L.P. bought a new stake in shares of MAIA Biotechnology during the first quarter valued at about $140,000. BlackRock Inc. purchased a new stake in shares of MAIA Biotechnology in the second quarter worth about $580,000. Finally, Cable Car Capital LP purchased a new stake in shares of MAIA Biotechnology in the second quarter worth about $741,000. Hedge funds and other institutional investors own 5.65% of the company's stock.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.
The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
